title: Efficacy of two different thiol-modified crosslinked hyaluronate formulations as vitreous replacement compared to silicone oil in a model of retinal detachment.
abstract: The efficacy of two novel artificial vitreous body substitutes (VBS) consisting of highly biocompatible thiolated cross-linked hyaluronic acid (HA)-based hydrogels in comparison to silicone oil in a model of retinal detachment was investigated. Pars plana vitrectomy (23G) was performed in the right eye of 24 pigmented rabbits. Retinal detachment of two quadrants was induced by creating a small retinotomy near the vascular arcade and injecting balanced salt solution (BSS) subretinally. The retina was reattached by injecting air, which was followed by increasing the infusion pressure, and the retinal tear was treated by endolaser photocoagulation. At the end of the procedure, the eye was filled either with 5000-cs silicone oil (after fluid air exchange) or the respective hydrogel (with two different viscosities). Follow-up examination included slit lamp examination, funduscopy, intraocular pressure measurements (IOP), optical coherence tomography (OCT) and electroretinogram (ERG) measurements. After a maximum follow-up of four weeks both eyes were removed, examined macroscopically, photographed, and prepared for histology. Of the eight rabbits that received silicone oil, seven (87.5%) developed a recurrent retinal detachment with pronounced proliferative vitreoretinopathy within the first two weeks after surgery. In contrast, in the hydrogel treated eyes, the retina stayed attached in the majority of the cases (73.3%). IOP and retinal morphology were normal as long as the retina remained re-attached. In conclusions, this model of retinal detachment, both thiolated crosslinked hyaluronate hydrogels showed superior efficacy when compared to silicone oil. These hydrogels have a promising potential as novel vitreous body substitutes.
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Schnichels
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.
authors.forename: Nele
authors.initials: N
authors.lastname: Schneider
authors.affiliation: Croma Pharma GmbH, Leobendorf, Austria.
authors.forename: Christine
authors.initials: C
authors.lastname: Hohenadl
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.
authors.forename: José
authors.initials: J
authors.lastname: Hurst
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Schatz
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.
authors.forename: Kai
authors.initials: K
authors.lastname: Januschowski
authors.affiliation: Centre of Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany.|Department of Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, Hamburg, Germany.
authors.forename: Martin S
authors.initials: MS
authors.lastname: Spitzer
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D003432:Cross-Linking Reagents / Q000737:chemistry; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D020100:Hydrogels / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D011817:Rabbits; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012163:Retinal Detachment / Q000601:surgery*; D012827:Silicone Oils / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D013438:Sulfhydryl Compounds / Q000737:chemistry; D014822:Vitreous Body / Q000601:surgery*
chemical_list: D001672:Biocompatible Materials; D003432:Cross-Linking Reagents; D020100:Hydrogels; D012827:Silicone Oils; D013438:Sulfhydryl Compounds; D006820:Hyaluronic Acid